CTOs on the Move

KalVista Pharmaceuticals

www.kalvista.com

 
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kalvista.com
  • 55 Cambridge Pkwy Suite 901E
    Cambridge, MS USA 02142
  • Phone: 857.999.0075

Executives

Name Title Contact Details

Funding

KalVista Pharmaceuticals raised $193.5M on 02/10/2021

Similar Companies

Encorium Group

Encorium Group, Inc is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Product Development

The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.

Paradigm Diagnostics

Paradigm is a medical diagnostics company serving physicians and patients worldwide.

Ben Venue Labs

Ben Venue Labs is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.